cemiplimab-rwlc

cemiplimab-rwlc (LIBTAYO) is an FDA-listed pharmaceutical active ingredient. Associated with Regeneron UK Limited. Route of administration: intravenous. Current US regulatory status: approved.

LIBTAYO is a marketed brand name for cemiplimab-rwlc. Check FDA Drugs@FDA for the current US label holder and prescribing information.

cemiplimab-rwlc has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.